Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: the case of glucagon-like peptide-1 receptor agonists

Abstract

This analysis found that a very small proportion of real‐world patients fit CVOT eligibility. The findings question whether any meaningful conclusions can be drawn from applying trial enrolment criteria to real‐world patients.

Citation
Sciannameo V, Berchialla P, Orsi E, et al. Diabetes Obes Metab 2020;22:817–27.